Featured
Drug approvals slide in Australia
After a mammoth year of prescription drug approvals in 2025, the registration of both new drugs and new indications for existing medicines in Australia appears to have lost momentum
Pipeline & Intellectual Property
AZ buys in before Summit's peak?
In what could be a savvy move, AZ has acquired more than 10 per cent of Summit Therapeutics ahead of much-hyped trial results
Regulatory & Reimbursement
October listing a win for complex condition
A treatment that provides a much-needed alternative option for people with atopic dermatitis has hit the PBS
Industry & Companies
Women in pharma hit milestone
Ahead of its much-anticipated end-of-year event next month, this fledgling Australian branch of a global networking group has already passed a major milestone
Featured
Patients pick ANZ's best pharma
The pharma with industry's best Corporate Reputation jumped five places to take the top spot, thanks to an overwhelming response from patients who had worked with the company
Industry & Companies
Biogen staff spread early Christmas cheer
The volunteering experience provided employees with a first-hand understanding of the scale of community need and the importance of supporting vulnerable Australians
Regulatory & Reimbursement
Govt trumpets groundbreaking cancer results
An 86 per cent complete response rate from a study that combined three drugs sponsored by AbbVie, BMS, and Roche has been shared by a State Government as part of its election commitment
Sales, Marketing & Public Relations
TV star speaks out for GSK campaign
At a high-profile campaign launch in the heart of Sydney's CBD, a much-loved celebrity revealed the impact this disease has had on her life and that of her family
Jobs & Workplace
Tax reform could force Aussie jobs overseas
Peak body for life sciences professionals warns a raft of Aussie pharma roles could move overseas if certain changes to the R&D Tax Incentive go through
Regulatory & Reimbursement
Time to use the C-word for multiple myeloma?
After analysing trial results which produced astounding results J&J is optimistic for a future where MM is no longer defined as incurable
Regulation & Legal
TGA goes to court over prescription meds
Australia’s medicines regulator has commenced proceedings in the Federal Court, alleging unlawful advertising of prescription-only medicines
Regulatory & Reimbursement
PBAC unpacks pet peeves about pharma
Lifting the lid on the frustrating mismatch between what the Committee says it needs in order to make a recommendation and what sponsors dish up
Featured
Who's Australia's Most Trusted (and Distrusted) pharma?
When it comes to trust and distrust two pharmas stand out, Australian research has found. See who's on a winning streak
Featured
Lilly hit by health industry backlash
Platform sparks outrage from pharmacists and doctors claiming the 'Americanisation' of Australian healthcare, an accusation the company vehemently denies
Jobs
Sales, Marketing & Public Relations
New tool puts KOLs on pharma's radar
Finding and validating KOLs across therapeutic areas just got a lot easier with a new AI-powered tool that does the heavy lifting for Medical Affairs teams
Industry & Companies
Missing data sinks Aussie Phase 3 trial
Interim analysis shuts down the Phase 3 trial of a flagship treatment after operational challenges resulted in missing data, throwing the future of the company into uncertainty
Regulatory & Reimbursement
First new drug in almost 20 years launched
CEO confirms plans to engage further with government and relevant stakeholders post launch, to assess the appropriate timing and pathway to a PBS listing
Featured
Trump nabs secret slice of Aussie drug prices
Documents obtained under Freedom of Information, suggest the US Government will share in the increased revenue pharmas generate by lifting drug prices outside the US
Regulatory & Reimbursement
Hyped drug approved after 5-plus years
The TGA has finally given the greenlight to a drug that was lodged with the regulator in 2021, with the sponsor actively pursuing reimbursement via MSAC and the PBS
Regulatory & Reimbursement
Takeda snaps up recently vacated market
With its competitor being deregistered at the end of 2024, Takeda has stepped in with the only vaccine of its kind Australia for a disease with more than 2600 cases a year
Industry & Companies
New office brings pharma team together
A change of headquarters to a brand new office space is planned to increase collaboration between teams
Industry & Companies
MA board voting opens: three leaders, two seats
Voting has opened to fill two vacancies on the Medicines Australia board with three leaders in the running
Industry & Companies
Pharma downsizes in Australia
This company is downsizing its office space following the latest restructuring in Australia, with an official move slated for the start of next month
Industry & Companies
Aussie staff let go as pharma put up for sale
A Sydney-based pharma is up for sale, with almost the entire workforce wiped out, following the appointment of a Voluntary Administrator
Leadership & People
Who made Australia's Most Powerful People list?
This high-flyer shot four places up the list to be named the third most powerful person in Australia this year - with PBS performance cited as a reason
Industry & Companies
Shares skyrocket 30% on new trial data
In one of the most competitive markets in the world, this company is looking to reinvent the space, and its latest topline trial results have impressed
- Regulatory & Reimbursement Changed global pricing sinks PBS listing
- Regulation & Legal Half of PBS drugs can now be prescribed by pharmacists
- Leadership & People Global genomics boss heading to Australia
- Industry & Companies Psychedelic medicines flying high
- Sales, Marketing & Public Relations Lilly goes direct for non-PBS meds
- Regulatory & Reimbursement Drug slated for PBS delisting gets more time
- Other News And again... Keytruda challenger shapes up
- Regulation & Legal Speed bump ahead for NZ fast-track?
- Regulatory & Reimbursement Nine pharmas seek to add new drug labels
- Jobs & Workplace Senior leadership shake-up sweeps industry
